Journal of BUON (Print ISSN: 1107-0625, Electronic ISSN: 2241-6293) is an independent Open Access Journal, published by BAKIS Productions LTD, and  appears exclusively on the internet. It is covered/indexed in PUBMED/MEDLINE, Science Citation Index Expanded (SCIE), SciSearch, Web of Science, Global Health, Current Awareness in Biological Sciences (BIO-BASE), EMBASE/Excerpta Medica, and SCOPUS.

JBUON appears to be bimonthly e-published journal with continuous volume, issue and page numbers.

AIMS AND SCOPE

JBUON aims at the rapid diffusion of scientific knowledge in Oncology.

Its character is multidisciplinary, therefore all aspects of oncologic activities are welcome including clinical research (medical oncology, radiation oncology, surgical oncology, nursing oncology, psycho-oncology, supportive care), as well as clinically-oriented basic and laboratory research, cancer epidemiology and social and ethical aspects of cancer. Experts of all these disciplines are included in the Editorial Board.

With a rapidly increasing body of new discoveries in clinical therapeutics, the molecular mechanisms that contribute to carcinogenesis, advancements in accurate and early diagnosis etc, JBUON offers a free forum for clinicians and basic researchers to make known promptly their achievements around the world.

With this aim JBUON accepts a broad spectrum of articles such as editorials, original articles, reviews, special articles, short communications, commentaries, letters to the editor and correspondence among authors and readers.

EDITORIAL POLICIES

PEER REVIEW POLICY

JBUON aims to ensure that articles are unbiased, scientifically accurate and clinically relevant via a rigorous peer-review process. The suitability of each manuscript (whether it falls within the scope of JBUON) is assessed by the Editor-in-Chief and Associate Editors. Submissions judged as weak or otherwise inappropriate, will be rejected promptly by the editors without external review. Articles that have passed the preliminary examination (including: initial evaluation by the editors, plagiarism detection and image manipulation screening) will be sent for external peer review by an average of 3-6 reviews (at least two). Reviewers are selected based on the experts’ field. Peer review is performed on a double-blind basis – the identities of peer reviewers and authors are kept confidential. Peer reviewers must disclose potential conflicts of interests that may affect their ability to provide an unbiased appraisal. The editors reserve the right to reject or to return the manuscript to the author(s) for additional revisions.

ANTI-PLAGIARISM POLICY

JBUON follows the core practices of the Committee on Publication Ethics (COPE) and Council of Science Editors. JBUON detects plagiarism in all the submitted manuscripts using the software (iThenticate’s CrossCheck).

Images submitted to JBUON are screened for manipulation. Authors should retain the raw data, as editors may request them to provide when neccessary. JBUON disapproves any kind of malpractice and unethical practice.

PERMISSIONS

Written permission to reproduce borrowed material (illustrations, tables and photographs) must be obtained. Authors must ensure that appropriate permission has been obtained for the publication of identifiable clinical photographs. Borrowed and previously published material should be acknowledged in the captions in this style: “Reproduced by kind permission of… (publishers) … from … (reference)”. It is the responsibility of the author to obtain all such permissions from the original publishers and authors, and to submit them with the manuscript.

AUTHORSHIP

The journal’s definition of what qualifies as authorship is based on the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, established by the International Committee of Medical Journal Editors (ICMJE). Authors are those who have contributed to the conception and design of the article, the acquisition of data, or the analysis and interpretation of data, as well as the writing of the article or the revision of its content; and have read and approved the final version of the article before submission.

ETHICS POLICY

Papers that contain results of human and/or animal studies will be accepted for publication only if it is made clear that a high standard of ethics was applied in carrying out the investigations.

When reporting experiments on human subjects, authors should indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study. Thus, papers reporting clinical studies should, where appropriate, contain a statement that they have been carried out with the ethical committee’s approval. For investigations involving human subjects, authors should explain how informed consent was obtained from the participants involved.

When reporting experiments on animals, authors should indicate whether the institutional and national guidelines for the care and use of laboratory animals were followed. Papers disregarding the welfare of experimental animals will be rejected. Authors may find the UKCCCR “Guidelines for the Welfare of Animals in Experimental Neoplasia” helpful in this regard. JBUON does not accept work that is funded in any part by tobacco industry sources.

PATIENT PRIVACY

Patients have a right to privacy that cannot be infringed without informed consent. Identifying information should not be included unless it is essential for scientific purposes and the patient (or parent or legal guardian) has given written informed consent for publication. Informed consent for this purpose requires that the manuscript to be published be shown to the patient. Informed consent shall be indicated in the manuscript. In attempting to maintain patient anonymity, identifying details should be omitted where unnecessary.However, patient data should not be modified or falsified. Informed consent should be obtained where there is any doubt that anonymity can be guaranteed.

CONFLICTS OF INTEREST

Authors are required to disclose all relevant financial support and potential conflicts of interest in their cover letter, within the manuscript, and on the copyright transfer agreement. If there are no financial disclosures from any author, this should be stated as well. In addition, authors have an ethical responsibility to ensure all research discussed in their work is credible and data are accurate prior to publication. Authors must also clearly identify in the manuscript any discussion of investigational or “off-label” use of drugs or medical devices. The authors will be required to submit such disclosures when submitting their manuscript in the cover letter. Only if conflicts of interest exist will this appear in the published form of the manuscript.

DATA SHARING  POLICY

JBUON strongly encourages that all datasets on which the conclusions of the paper depend should be available to readers, unless they are already provided as part of the submitted article. Where datasets are included in the study, authors should state clearly in the article where the data supporting their findings can be found. Authors who do not wish to share their data should also state why the data are unavailable.

POST-PUBLICATION POLICY

JBUON publishes three types of post-publication notices. 

  • Corrections
  • Expressions of Concern (EOCs)
  • Retraction notices

Refer to the details: JBUON Post Publication Policy.

ADVERTISING POLICY

Any inquiries or interest in advertising with JBUON can be sent to: editorial_office@jbuon.com

  • JBUON does not allow advertising to influence editorial decisions.
  • JBUON will not accept advertising for products or services known to be harmful to health (e.g. tobacco and alcohol products) .
  • All advertisements for drug specific campaigns should encourage correct and rational use and must not be misleading.
  • Advertisements may not be deceptive or misleading, and must be verifiable. 

LICENSING

All articles are published under a Creative Commons Attribution 4.0 International License. This means that you are free to:

  • Share — copy and redistribute the material in any medium or format
  • Adapt — remix, transform, and build upon the material
  • for any purpose, even commercially.

Under the following terms:

  • Attribution — You must give appropriate credit to JBUON and the article’s author(s) and provide a link to the article’s Issue in JBUON’s website. You may do so in any reasonable manner, but not in any way that suggests JBUON or the author(s) endorses you or your use.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

For information and instructions regarding article submission click here.

Reset link sent!

Link for password reset has been emailed to you. Please check your email.